| Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions? | |
| | |
MedLine Citation:
|
PMID: 21351863 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Aims: We investigated the extent to which adjusting for health-related quality of life (HRQoL) alters incremental cost per life-year gained ratios, and the implications for reimbursement decisions. Methods: We identified all cancer-related interventions in the Tufts Medical Center Cost-Effectiveness Analysis Registry in which both a cost/quality-adjusted life-year (QALY) and a cost/life-year ratio were reported in the same study. We assessed the ordinal relationship between these ratios and analyzed the extent to which using a cost/QALY rather than a cost/life-year ratio would potentially yield different reimbursement decisions. Results: The rank-order correlation between cost/life-year and cost/QALY ratio pairs was 0.917 (p < 0.0001). In 78.8% of comparisons, both cost/QALY and cost/life-year ratios were below a prespecified threshold (e.g., US$50,000 per QALY or life-year). Adjusting for HRQoL resulted in a higher ratio such that it crossed a prespecified threshold in 18.6% of interventions. The data suggest that adjusting life-years for HRQoL does not substantively affect cost per life-year ratios for the vast majority of cancer-related interventions. Conclusion: Our analysis implies that the method used for HRQoL adjusting or even HRQoL adjusting at all does not matter for most reimbursement decisions on life-saving interventions. The results could differ for interventions that have large impacts on patients' HRQoL compared with the impact on survival. |
| | |
Authors:
|
Dan Greenberg; Peter J Neumann |
Related Documents
:
|
3226823 - Comparison of the 1979 and the 1986 norms on the standard progressive matrices for econ... 3206283 - School screening for scoliosis by the chiba university medical school screening program... 17808703 - The hasanlu project: archeologists, working with natural scientists, delineate life in ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert review of pharmacoeconomics & outcomes research Volume: 11 ISSN: 1744-8379 ISO Abbreviation: Expert Rev Pharmacoecon Outcomes Res Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-02-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101132257 Medline TA: Expert Rev Pharmacoecon Outcomes Res Country: England |
Other Details:
|
Languages: eng Pagination: 113-9 Citation Subset: IM |
Affiliation:
|
The Center for the Evaluation of Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Modeling correlated healthcare costs.
Next Document: Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement ...